All In Biotech

Free tool

FAERS Monitor: Gonal-F Rff Redi-Ject

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 021684 or its brand name (Gonal-F Rff Redi-Ject, Follitropin Alfa/Beta). Reports on generic versions are filed under their own applications.

Reports

54

Serious

46

85% of reports

Hospitalization

21

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • ovarian hyperstimulation syndrome21
  • off label use7
  • foetal exposure during pregnancy6
  • maternal exposure during pregnancy5
  • abdominal distension4
  • arnold-chiari malformation4
  • drug interaction4
  • exposure during pregnancy4
  • hyperthyroidism4
  • spina bifida4
  • dyspnoea3
  • optic nerve sheath meningioma3
  • palpitations3
  • tachycardia3
  • abdominal discomfort2

Reports by year received

View as table
YearReports
20161
20181
20194
20209
20212
20227
20239
20249
20256
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,105 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
optic nerve sheath meningiomaSignal361561.718764.0110,760
ovarian hyperstimulation syndromeSignal213541.42528.770,199
arnold-chiari malformationSignal41641.6638.05,000
spina bifidaSignal4749.4291.62,284
hyperthyroidismSignal4107.741.9323
foetal exposure during pregnancySignal628.813.5135
exposure during pregnancySignal425.19.870
maternal exposure during pregnancySignal521.99.580
abdominal distensionSignal414.95.839
tachycardiaSignal313.24.423
palpitationsSignal310.03.316
drug interactionSignal49.83.824
abdominal discomfort24.61.23
off label useSignal73.11.68
dyspnoea32.10.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.